Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China

By Andrew Silver SHANGHAI (Reuters) - Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatmen...

Related Keywords

Huadong ,Guangdong ,China ,Shanghai ,Japan ,Copenhagen ,Køavn ,Denmark ,Danish ,Chinese ,Maggie Fick ,Andrew Silver ,Zuo Ya Jun ,Miyoung Kim ,Clarivate Verma ,Karan Verma ,Eli Lilly ,Muralikumar Anantharaman ,Jacob Gronholt Pedersen ,Maziar Mike Doustdar ,Novo Nordisk ,Sihuan Pharmaceutical Holdings Group ,Goldman Sachs ,Reuters ,Danish Krone ,Hangzhou Jiuyuan Gene Engineering ,United Laboratories ,Huadong Medicine ,Sihuan Pharmaceutical Holdings ,Shanghai Benemae Pharmaceutical ,